Dual‐Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H ₂ Burst and Cascade Catalytic ROS Birth to Repress Cancer

Single or combined ROS therapy will induce cancer resistance after long-term medication cure. Although currently concurrent H₂/ROS therapy is a promising method, the mutual reaction between H₂ and ROS dampens their efficiency. To address this issue, g-C₃N₄-based dual-heterojunctions, i.e., N-doped carbon nanoribbons (N-CNB)/g-C₃N₄ and core-shell-structured Au@Pd nanoparticles/g-C₃N₄, respectively, are constructed to decode alternate H₂/ROS therapy. Therein, N-CNB/g-C₃N₄ heterojunctions enhance near-infrared (NIR) photoabsorption to unlock photocatalytic H₂ evolution, and Au@Pd/g-C₃N₄ heterojunctions unlock the inherent and newly-emerging bioenzymes-like catalytic ROS birth. In this alternate H₂/ROS therapy, photocatalytic H₂ evolution and multienzymically-catalytic ROS birth are alternately decoded under NIR "on" and "off", respectively, because the photoirradiation-triggered structural shift insensitive to photothermal effects is reversible in response to NIR "on" and "off", displaying a temporal controllability. The alternate H₂/ROS therapy expedites the infiltrations and intratumoral proliferation of anti-tumor immune cells including CTLs and Th17, hampers the infiltrations of exhausted CD8+ T cells and Tregs, and downregulates resistance-associated proteins (PARP, EpCAM, and CD133). These actions cooperatively activate robust immune responses, attenuate anti-tumor immunity confinements, and cancer resistance to suppress common and Sorafenib-induced resistant liver cancer. This work offers distinctive insights into cancer resistance removal.